Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159679 · ClinicalTrials.gov registry record · Phase 4
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 167
- Enrollment target
NCT00159679 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 167 participants.
The verdict
NCT00159679, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.
Interventions
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00159679
The ClinicalTrials.gov registry entry for NCT00159679 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pregabalin is the first listed.
NCT00159679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00159679 about?
NCT00159679 is a clinical study titled "Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy". The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.
What is the current status of trial NCT00159679?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 167 participants. The study started on 2004-09. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00159679?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00159679?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.